
PharmaEssentia Resubmits Ropeginterferon alfa-2b-njft Application to the US FDA to Treat Polycythemia Vera (PV)
PharmaEssentia USA Corporation, a global biopharmaceutical innovator, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced th ...